

adrenocorticotrophic hormone (ACTH), brain natriuretic polypeptide, cholecystokinin, corticotropin releasing factor, diazepam binding inhibitor fragment, FMRF-amide, galanin, gastric releasing polypeptide, gastric inhibitory polypeptide, gastrin, gastrin releasing peptide, glucagon, glucagon-like peptide-1, glucagon-like peptide-2, LHRH, melanin concentrating hormone, melanocyte stimulating hormone (MSH), alpha-MSH, morphine modulating peptides, motilin, neurokinin A, neurokinin B, neuromedin B, neuromedin C, neuromedin K, neuromedin N, neuromedin U, neuropeptide K, neuropeptide Y, pituitary adenylate cyclase activating polypeptide (PACAP), pancreatic polypeptide, peptide YY, peptide histidine-methionine amide (PHM), secretin, somatostatin, substance K, substance P have been mentioned in line 4, OUT, thyrotropin-releasing hormone (TRH), kyotorphin, melanostatin (MIF-1), thrombopoeitin analogs, in particular AF 12505, insulin-like growth factor I, insulin-like growth factor II, growth hormone (GH)-releasing peptide-6 (GHRP-6), beta-Interleukin I, beta-Interleukin II, Interleukin II, exendin-4 (GLP-1 analog, exendin-3 (GLP-1 analog)], epidermal growth factor, bivalirudin (Hirulog), hirulog-1, C-type natriuretic peptide, Melanotan-II, thymosin alpha1 (TA1), ornipressin), octreotide, eptifibatide (INTEGRILIN), calcitonin gene-related peptide (CGRP) ndomorphin-1; endomorphin-2, nociceptin (also known as Orphanin FQ, angiotensinogen , adrenomodullin (1-12), antiarrhythmic peptide (AAP), Antagonist G, indolicidin, osteocalcin, cortistatin 29 (1-13), cortistatin 14, PD-145065, PD-142893, fibrinogen binding inhibitor peptide, leptin (93-105), GR 83074, Tyr-W-MIF-1.

The Examiner asserts that a sequence listing is required for each of the foregoing peptides since the sequence listing will aid in the search. It is asserted that since a search of the claimed invention already exceeds the "undue burden" threshold, the additional time required to find all of the sequences would be entirely unreasonable.

The Examiner's request is duly noted. However, Applicants disagree with the assertion that a Sequence Listing is required for each of the peptides disclosed above. Applicants respectfully point out that 37 C.F.R. § 1.821 et seq. specifically encompasses disclosed peptide sequences. Peptide sequences are disclosed only for some not all of the listed peptides. Sequence Listings are not required for nondisclosed peptide sequences.

The Examiner is hereby invited to contact the undersigned if there are any questions regarding this response.

Respectfully submitted,

Date: 12/1/00

Cheryl H. Agris

Cheryl H. Agris, Reg. No. 34,086  
Attorney at Law  
P.O. Box 806  
Pelham, N.Y. 10803